DNAPRINT GENOMICS

As of September 30, 2007, DNAPRINT GENOMICS carries a market capitalization of 4.06M, placing it among publicly traded companies globally. Its enterprise value stands at 9.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2007, DNAPRINT GENOMICS has 644.61M shares outstanding.

These figures are as of September 30, 2007. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at -0.48.

As of September 30, 2007, DNAPRINT GENOMICS trades at an EV/EBITDA multiple of 1.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.47 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.25M versus a market cap of 4.06M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2007, DNAPRINT GENOMICS maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2007. Return on assets (ROA) is negative at -121.24, reflecting losses generated across the asset base. The company generates approximately 77,248.32 in revenue per employee across its workforce of 25.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.12 indicates how many times DNAPRINT GENOMICS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2007, DNAPRINT GENOMICS generated 1.93M in revenue and converted that into -4.55M in net income, yielding earnings per share of -0.01. EBITDA reached 7.12M, while operating income came in at -6.31M.

As of September 30, 2007, DNAPRINT GENOMICS holds 134,347.00 in cash and equivalents against 5.33M in total debt, resulting in a net debt position of 5.15M. Total book value stands at -8.39M, with working capital of -9.35M providing operational flexibility.

DNAPRINT GENOMICS produced -4.14M in operating cash flow over the twelve months ended September 30, 2007. After subtracting -164,998.00 in capital expenditures, free cash flow totaled -4.31M - equivalent to -0.01 per share.

Over the twelve months ended September 30, 2007, DNAPRINT GENOMICS posted a gross margin of 23.11, reflecting its pricing power and cost economics. The operating margin of -326.54 and net profit margin of -235.64 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2007. Free cash flow yield is negative at -125.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 37.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to DNAPRINT GENOMICS shareholders.

DNAPRINT GENOMICS's most recent stock split took place on July 12, 2005 with a 20:1 split ratio.

As of September 30, 2007, DNAPRINT GENOMICS has an Altman Z-Score of -31.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.